|
1）Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011; 117: 3025-31
|
|
|
|
2）Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011; 118: 529-34
|
|
|
|
|
|
3）Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011; 29: 1627-33
|
|
|
|
|
|
4）Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117: 4691-5
|
|
|
|
|
|
5）Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010; 28: 2077-84
|
|
|
|
|
|
6）Sarasquete ME, Garcia-Sanz R, González D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic- specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005; 90: 1365-72
|
|
|
|
|
|
7）Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012; 159: 499-513
|
|
|
|
|
|
8）Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up- front autologous transplantation. Blood. 2011; 118: 5989-95
|
|
|
|
|
|
9）Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013; 121: 884-92
|
|
|
|
|
|
10）Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-55
|
|
|
|
|
|
11）Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-700
|
|
|
|
|
|
12）Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013; 88: 360-76
|
|
|
|
|
|
13）Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013; 27: 711-7
|
|
|
|
|
|
14）Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010; 115: 4168-73
|
|
|
|
|
|
15）Nooka A, Lonial S. Sequential or combination therapy for multiple myeloma. Expert Rev Hematol. 2012; 5: 533-45
|
|
|
|
|
|
16）McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1770-81
|
|
|
|
|
|
17）Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366: 1759-69
|
|
|
|
|
|
18）Kumar S. Risk of early death in multiple myeloma. Clin Adv Hematol Oncol. 2012; 10: 172-4
|
|
|
|
|
|
19）Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118: 4519-29
|
|
|
|
|
|
20）Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963; 185: 914-9
|
|
|
|
|
|
21）Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9: 179-86
|
|
|
|
|
|
22）Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83
|
|
|
|
|
|
23）Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120: 1067-76
|
|
|
|
|
|
24）Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12: 335-48
|
|
|
|
|
|
25）Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smoldering disease. Br J Haematol. 2007; 109: 1692-700
|
|
|
|
|